Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | CCR4 | P51679 | 4/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20714714 | 0.83 | CCR2 (0.59) | MCOLN3TSHRCCR2KMT2APTGES2 | |
| SCHEMBL30720453 | 0.81 | HSD11B1 (0.51) | MCOLN3TSHRCCR2LMNAAKR1B1 | |
| SCHEMBL1248188 | 0.81 | AKR1B1 (0.56) | MCOLN3TSHRLMNAKMT2APTGES2 | |
| SCHEMBL395266 | 0.81 | HSD11B1 (0.51) | MCOLN3TSHRCCR2LMNAAKR1B1 | |
| SCHEMBL28650941 | 0.80 | HSD11B1 (0.40) | MCOLN3TSHRCCR2LMNAKMT2A | |
| SCHEMBL2642804 | 0.80 | HSD11B1 (0.44) | MCOLN3TSHRCCR2LMNAKMT2A | |
| SCHEMBL3277048 | 0.80 | HSD11B1 (0.50) | MCOLN3CCR2HSD11B1CCR4 | |
| SCHEMBL7972629 | 0.79 | HTT (0.46) | TSHRCCR2LMNAHSD11B1PTGS2 | |
| SCHEMBL29519135 | 0.79 | TSHR (0.53) | MCOLN3TSHRLMNAKMT2APTGES2 | |
| SCHEMBL5607122 | 0.79 | TSHR (0.53) | MCOLN3TSHRLMNAKMT2APTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718605-B1 | PROCESSES FOR THE PREPARATION OF ARYL-AND HETEROARYL-ALKYLSULFONYL HALIDES | WYETH CORP (US) | 2009-06-17 | — | — | EP | claimed |
| EP-3453702-A2 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | Merial, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017129944-A1 | TRACER AND METHOD | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-08-03 | — | — | WO | disclosed |
| US-9695129-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695129-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160251317-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL INC (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160251317-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL INC (US) | 2016-09-01 | — | — | US | disclosed |
| US-9359305-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359305-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9169251-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2015-10-27 | — | — | US | disclosed |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080312230-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | MSD K.K. (JP) | 2008-02-07 | — | — | US | disclosed |
| WO-2007068418-A1 | USE OF PYRROLO [2 , 3-B] PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| EP-1734040-A1 | SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | CCR1, CCL2, CCL11 | MCOLN3 1156/4885TSHR 949/4885CCR2 6/4885 |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | MCOLN3 4489/4885TSHR 3404/4885CCR2 658/4885 |
| US-20160251317-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | LIPC, CYP3A43, CYP51A1 | MCOLN3 963/4885TSHR 4248/4885CCR2 3214/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | MCOLN3 2167/4885TSHR 1602/4885CCR2 574/4885 |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | GCK, GCKR, PDXK | MCOLN3 4156/4885TSHR 2323/4885CCR2 2361/4885 |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | IFNG, IRF3, IFNAR1 | MCOLN3 3721/4885TSHR 4108/4885CCR2 133/4885 |
| US-20080312230-A1 | Organic Compounds | OPRM1, OPRL1, OPRD1 | MCOLN3 551/4885TSHR 1448/4885CCR2 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.